KR20200108494A - 근위축성 측삭 경화증 치료제 - Google Patents

근위축성 측삭 경화증 치료제 Download PDF

Info

Publication number
KR20200108494A
KR20200108494A KR1020207026038A KR20207026038A KR20200108494A KR 20200108494 A KR20200108494 A KR 20200108494A KR 1020207026038 A KR1020207026038 A KR 1020207026038A KR 20207026038 A KR20207026038 A KR 20207026038A KR 20200108494 A KR20200108494 A KR 20200108494A
Authority
KR
South Korea
Prior art keywords
als
ghrelin
mice
group
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020207026038A
Other languages
English (en)
Korean (ko)
Inventor
츠요시 마츠오
노리히토 무라야마
마유미 후루야
Original Assignee
다이이찌 산쿄 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이이찌 산쿄 가부시키가이샤 filed Critical 다이이찌 산쿄 가부시키가이샤
Priority to KR1020227012378A priority Critical patent/KR102499918B1/ko
Publication of KR20200108494A publication Critical patent/KR20200108494A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
KR1020207026038A 2012-10-24 2013-10-23 근위축성 측삭 경화증 치료제 Withdrawn KR20200108494A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227012378A KR102499918B1 (ko) 2012-10-24 2013-10-23 근위축성 측삭 경화증 치료제

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012234300 2012-10-24
JPJP-P-2012-234300 2012-10-24
PCT/JP2013/078743 WO2014065341A1 (ja) 2012-10-24 2013-10-23 筋萎縮性側索硬化症治療剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157010085A Division KR20150070180A (ko) 2012-10-24 2013-10-23 근위축성 측삭 경화증 치료제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227012378A Division KR102499918B1 (ko) 2012-10-24 2013-10-23 근위축성 측삭 경화증 치료제

Publications (1)

Publication Number Publication Date
KR20200108494A true KR20200108494A (ko) 2020-09-18

Family

ID=50544716

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020207026038A Withdrawn KR20200108494A (ko) 2012-10-24 2013-10-23 근위축성 측삭 경화증 치료제
KR1020157010085A Ceased KR20150070180A (ko) 2012-10-24 2013-10-23 근위축성 측삭 경화증 치료제
KR1020227012378A Active KR102499918B1 (ko) 2012-10-24 2013-10-23 근위축성 측삭 경화증 치료제

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020157010085A Ceased KR20150070180A (ko) 2012-10-24 2013-10-23 근위축성 측삭 경화증 치료제
KR1020227012378A Active KR102499918B1 (ko) 2012-10-24 2013-10-23 근위축성 측삭 경화증 치료제

Country Status (11)

Country Link
US (1) US20150265680A1 (https=)
EP (1) EP2913063B1 (https=)
JP (1) JP6262661B2 (https=)
KR (3) KR20200108494A (https=)
CN (2) CN104853778A (https=)
AU (1) AU2013335678B9 (https=)
BR (1) BR112015009107A2 (https=)
CA (1) CA2889499C (https=)
IN (1) IN2015DN04172A (https=)
RU (1) RU2655811C2 (https=)
WO (1) WO2014065341A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106636A (zh) 2014-11-12 2017-08-29 利瑞克药品有限公司 肠内喂养不耐受的治疗
WO2017083882A1 (en) * 2015-11-11 2017-05-18 Lyric Pharmaceuticals Inc. Treatment of enteral feeding intolerance and other conditions using ulimorelin analogs
US12429487B2 (en) 2018-12-06 2025-09-30 Biogen Ma Inc. Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis
KR20250107210A (ko) 2022-11-03 2025-07-11 루모스 파마, 인크. 이부타모렌의 압축형 경구 제형

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047558A1 (en) 1999-12-28 2001-07-05 Kaken Pharmaceutical Co., Ltd. Nerve protective drugs
JP2005239712A (ja) 2004-01-30 2005-09-08 Kaken Pharmaceut Co Ltd 神経突起伸展剤
WO2007146046A2 (en) 2006-06-07 2007-12-21 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
JP2008127377A (ja) 2006-11-24 2008-06-05 Jichi Medical Univ Ｇｈｓ−ｒ作動薬を含有してなるメタボリックシンドローム又は高血圧症の予防・治療剤。
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
US20120080747A1 (en) 2008-03-27 2012-04-05 Hynix Semiconductor Inc. Semiconductor Device

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668254A (en) 1990-05-11 1997-09-16 Romano Deghenghi D-2-alkyl-tryptophan and peptides containing same
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
CA2340701C (en) 1998-08-20 2009-05-26 Sumitomo Pharmaceuticals Co., Ltd. Oxindole derivatives as growth hormone releasers
ES2401939T3 (es) 1999-07-23 2013-04-25 Kenji Kangawa Nuevos péptidos
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
ATE370119T1 (de) 2000-06-13 2007-09-15 Zentaris Gmbh Wachstumhormonsekretionsförderer
CN100491395C (zh) 2002-04-11 2009-05-27 阿斯比奥制药株式会社 修饰肽的制造方法
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2006079077A2 (en) * 2005-01-20 2006-07-27 Acadia Pharmaceuticals Inc. Use of diltiazem or analogs thereof as modulators of ghrelin receptor
CA2625341A1 (en) * 2005-10-18 2007-04-26 Ono Pharmaceutical Co., Ltd. Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis
JP5173018B2 (ja) * 2008-04-03 2013-03-27 エフ．ホフマン−ラ ロシュ アーゲー 神経筋障害の処置のためのｐｅｇ化ｉｇｆ−ｉ変異体の使用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047558A1 (en) 1999-12-28 2001-07-05 Kaken Pharmaceutical Co., Ltd. Nerve protective drugs
JP2005239712A (ja) 2004-01-30 2005-09-08 Kaken Pharmaceut Co Ltd 神経突起伸展剤
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
WO2007146046A2 (en) 2006-06-07 2007-12-21 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
JP2008127377A (ja) 2006-11-24 2008-06-05 Jichi Medical Univ Ｇｈｓ−ｒ作動薬を含有してなるメタボリックシンドローム又は高血圧症の予防・治療剤。
US20120080747A1 (en) 2008-03-27 2012-04-05 Hynix Semiconductor Inc. Semiconductor Device

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
Amyotrophic Lateral Sclreosis (2010 년) 11 권 38-45 페이지
Experimental Neurology (2007 년) 207 권 52-63 페이지
Experimental Neurology (2011 년) 230 권 114-122 페이지
Expert Opinion on Emerging Drugs (2011 년) 16 권 (2 호) 537-558 페이지
Journal of Neurology (2011 년) 258 권 (4 호) 613-617 페이지
Korean Journal of Physiology and Pharmacology (2012 년) 16 권 (1 호) 43-48 페이지
Muscle & Nerve (1993 년) 16 권 (6 호) 624-633 페이지
Nature (1999 년) 402 권 656-660 페이지
Nature Neuroscience (2010 년) 13 권 (7 호) 877-883 페이지
Neurology (2008 년) 70 권 1004-1009 페이지
Neurology (2008 년) 71 권 1770-1775 페이지
Neurotoxicity Research (2011 년) 19 권 195-209 페이지
Physiological Reviews (2005 년) 85 권 495-522 페이지
Pulmonary Pharmacology & Therapeutics (2008 년) 21 권 (5 호) 774-779 페이지

Also Published As

Publication number Publication date
WO2014065341A1 (ja) 2014-05-01
CA2889499C (en) 2019-09-10
RU2015119472A (ru) 2016-12-20
AU2013335678A1 (en) 2015-05-21
EP2913063A1 (en) 2015-09-02
KR102499918B1 (ko) 2023-02-14
CN110354265A (zh) 2019-10-22
KR20150070180A (ko) 2015-06-24
AU2013335678B9 (en) 2024-12-12
AU2013335678B2 (en) 2017-10-26
KR20220051418A (ko) 2022-04-26
RU2655811C2 (ru) 2018-05-29
CA2889499A1 (en) 2014-05-01
JP6262661B2 (ja) 2018-01-17
BR112015009107A2 (pt) 2017-11-14
US20150265680A1 (en) 2015-09-24
JPWO2014065341A1 (ja) 2016-09-08
CN104853778A (zh) 2015-08-19
IN2015DN04172A (https=) 2015-10-16
EP2913063B1 (en) 2019-09-11
EP2913063A4 (en) 2016-07-20
HK1214152A1 (en) 2016-07-22

Similar Documents

Publication Publication Date Title
US11298403B2 (en) Therapeutic agent for inflammatory bowel disease
JP7229284B2 (ja) グルカゴン類似ペプチド－１受容体亢進剤を含む筋減少症治療用薬学組成物
CN101466399B (zh) 稳定的胰岛素样生长因子多肽
RU2707191C2 (ru) Нейродегенеративные расстройства
KR102239075B1 (ko) IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 근감소증의 예방 또는 치료용 약학 조성물
KR102499918B1 (ko) 근위축성 측삭 경화증 치료제
CN111417647A (zh) 新型senolytic肽
JP5999712B2 (ja) 高体温治療剤
JP7016125B2 (ja) 脳梗塞の治療薬
JP4748639B2 (ja) 肝臓疾患治療剤
EP1827481A2 (en) A composition comprising pp for the treatment of gastrointestinal disorders
US20080125360A1 (en) Composition Comprising Pyy for the Treatment of Gastrointestinal Disorders
WO2005110467A1 (en) A composition comprising pyy for the treatment of gastrointestinal disorders
HK1214152B (en) Therapeutic agent for use in treating amyotrophic lateral sclerosis
KR20180027924A (ko) 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물
KR20250023259A (ko) 근육 감소 억제 효과를 갖는 갈색거저리 유충 단백 가수분해 펩타이드 조성물
Class et al. Patent application title: Antagonists of the Interleukin-1 Receptor Inventors: Vladimir Berezin (Copenhagen N, DK) Vladimir Berezin (Copenhagen N, DK) Elisabeth Bock (Charlottenlund, DK) Assignees: SERODUS ASA

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200909

Application number text: 1020157010085

Filing date: 20150420

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201008

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201207

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220114

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220413

Application number text: 1020157010085

Filing date: 20150420

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20220414

WITB Written withdrawal of application